Scribe Therapeutics filed a Form S-1 registration statement with the Securities and Exchange Commission on July 2, 2026 (accession 0001193125-26-294804), the first public step toward an initial public offering. The document states the company has applied to list its common stock on the Nasdaq stock market under the symbol "SCTX," and that the closing of the offering is contingent on that listing being granted. What the filing does not yet contain is a number: the shares offered, the assumed price per share, and the estimated net proceeds are all left blank, marked in the prospectus as placeholder "$ million" figures pending the price range set later in the process.

That blank is standard for an initial S-1. Underwriters and issuers file the registration to start the SEC review clock and circulate a preliminary prospectus; the size and price get penciled in through subsequent amendments once the roadshow sets a range. So the honest reading of this filing is that Scribe has declared its intent to go public and named its ticker, but the amount of capital it is seeking is not disclosed here. The filing does specify the mechanics that are set: the company has granted its underwriters a 30-day option to purchase additional shares, and it identifies itself as an emerging growth company and a non-accelerated filer, the reduced-disclosure status that lets newer registrants scale back certain reporting.

We have applied to list our common stock on Nasdaq under the symbol “SCTX.” The closing of this offering is contingent upon such listing.— Scribe Therapeutics, Form S-1, sec.gov

What the company is, per the filing

Scribe describes itself as a clinical-stage biotechnology company "engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention." The registration states its focus is cardiovascular and metabolic disease, with initial programs aimed at drivers of atherosclerotic cardiovascular disease, or ASCVD. Where much of the gene-editing field has concentrated on rare disorders, the prospectus positions Scribe's technologies for common diseases — a category framing rather than a claim about results. The company reports it operates from Alameda, California, and lists Benjamin L. Oakes, Ph.D., as chief executive officer.

The platform description in the filing centers on two named toolsets. The lead program, STX-1150, is built on what the company calls ELXR, an engineered epigenetic-silencing technology that the prospectus says is designed to lower LDL cholesterol without making permanent genetic changes. A second component, which the filing labels XE, is described as a proprietary CasX-derived enzyme delivered with liver-targeted lipid nanoparticles. Those are the disclosed technology categories — an epigenetic-silencing approach and a non-Cas9 nuclease — and this article reports them as the company characterizes them, not as validated outcomes.

Pipeline status as a disclosure fact

The S-1 lays out three programs by development stage. STX-1150 is the lead candidate; the company states it secured regulatory clearance from Australia's Therapeutic Goods Administration and initiated a first-in-human clinical trial there in up to 64 adults with elevated LDL-C and increased ASCVD risk. Scribe writes that it anticipates reporting initial data from that trial, including safety, tolerability, and LDL-C-lowering activity, in the first half of 2027. Two earlier-stage programs follow: STX-1200 and STX-1400, which the filing says target elevated Lp(a) and severely high triglycerides by editing the LPA and APOC3 genes, respectively. These are stated as program descriptions and timelines drawn from the registration — disclosure facts about where each program sits, not assertions about whether any of them will work.

The filing frames the market opportunity by citing external data: it states that, according to the American Heart Association, someone in the United States suffers a heart attack every 40 seconds and heart disease costs the nation more than $400 billion a year. Those figures are the company's cited rationale for pursuing a prevalent-disease strategy; they belong to the AHA as quoted, not to Scribe's own results.

Use of proceeds, and the capital structure behind the raise

Because the dollar amount is blank, the interesting part of the financing disclosure is the allocation language, which is filled in even where the totals are not. The prospectus states Scribe intends to use the net proceeds, together with existing cash, across four buckets: to advance STX-1150; to advance STX-1200 and STX-1400; for continued investment in additional pipeline programs and the associated CRISPR technologies ELXR and XE, plus new technologies and its internal pipeline; and for working capital and general corporate purposes. The company adds that it may use a portion to in-license, acquire, or invest in complementary technologies, assets, manufacturing capabilities, or intellectual property. Each program-specific line carries its own placeholder — "approximately $ million to advance the development of" — so the split among programs is not quantified in this draft either.

The capitalization detail that is disclosed sets the pre-money baseline. The filing states that the share count outstanding after the offering is based on 14,616,718 shares of common stock outstanding as of March 31, 2026, a figure that already gives effect to three conversions triggered by the IPO's closing: a preferred stock conversion, a warrant conversion, and a note conversion. That structure — preferred, warrants, and convertible notes all rolling into common at the listing — is the typical venture-backed cap table resolving into public equity. Separately, the prospectus discloses 6,993,919 shares issuable on exercise of options outstanding under the company's 2018 Stock Incentive Plan at a weighted-average exercise price of $1.21 per share, an overhang that sits below any plausible IPO price and will dilute holders as options are exercised.

For a capital-markets reader, the takeaway is what is knowable today versus what is not. Knowable: Scribe has filed, chosen a ticker, tied its close to a Nasdaq listing, granted the standard over-allotment option, and told investors which programs the money is meant to fund. Not yet knowable: how much it is raising, at what price, and therefore what the dilution to the roughly 14.6 million existing shares actually looks like. Those numbers arrive in an amended S-1 with the price range, and only then can runway and dilution be computed rather than sketched. The filing also carries the boilerplate risk-factor caveat that management will have broad discretion over the proceeds and that investors will not, as part of their decision, get to assess how those proceeds are ultimately applied.

None of this is a verdict on the science or the deal. The registration is a disclosure event: it puts Scribe's business description, platform categories, program status, and intended use of proceeds on the public record, and it starts the SEC's review. The next data point that matters for the raise is the amendment that replaces the blanks — the price range and share count — which converts this from an announced intention into a sized offering.